Lobbying organisation

MS Canada

27 meetings with public office holders, Jun 12, 2025 to Jul 22, 2026.

766 meetings on record since 2009, their first on record.

Meetings over time

  • Jun 2025: 2 meetings, with Mark Carney, François-Philippe Champagne, Patty Hajdu, Marjorie Michel, Gregor Robertson
  • Jul 2025: 0 meetings
  • Aug 2025: 1 meeting, with Amen Ben Ahmouda
  • Sep 2025: 1 meeting, with Mark Carney, Marc-André Blanchard, Tim Krupa, Katharine Heus, Shaili Patel
  • Oct 2025: 2 meetings, with Jacob Mantle, Brad Redekopp, Margaret Dawn Anderson, Jennifer McKelvie, Pat Duncan
  • Nov 2025: 2 meetings, with Nina Cluny, Janice Charette, Charu Kaushic, Patricia Conrod, Jaeda Schilke
  • Dec 2025: 3 meetings, with Leslie Church, Wayne Long, François-Philippe Champagne, Grant Jackson
  • Jan 2026: 1 meeting, with Shalene Curtis-Micallef
  • Feb 2026: 0 meetings
  • Mar 2026: 4 meetings, with Annie Koutrakis, Carlos Leitão, Karim Bardeesy, Mélanie Joly, Kody Blois
  • Apr 2026: 0 meetings
  • May 2026: 6 meetings, with Manuela Tomic, Robert Morrissey, Judy Sgro, Sean Casey, Steven Bonk
  • Jun 2026: 3 meetings, with Mackenzy Metcalfe, Fahim Khan, Victoria Perak, Brendan Hanley, Helena Jaczek
  • Jul 2026: 2 meetings, with Raquel Dancho, Michael D. Chong, Justine Frame, Fatoumata Bah
Jun 2025peak 6 in a monthJul 2026

Hover or focus a month to see who was met.

What they lobby about

The registry's own subject categories, chosen by the lobbyist on each filing. Each one opens its own page.

Who they met

The 40 most-met of 124 people named in these filings.

House of Commons (133) · Senate of Canada (14) · Prime Minister's Office (PMO) (12) · Innovation, Science and Economic Development Canada (ISED) (7) · Canada Revenue Agency (CRA) (4) · Canadian Institutes of Health Research (CIHR) (4)

In their own words

  • We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV).
  • Access to treatments as it relates to the current regulatory and price negotiation processes to enhance timely access to all Health Canada approved MS disease-modifying therapies, with respect to the National Strategy for Drugs for Rare Diseases and national pharmacare.
  • Federal Budget: Allocate funding for the Canada Disability Benefit, the Employment Insurance Sickness Benefit; health research; access to treatment and care; and other budgetary policy as it relates to MS.

Meetings from the Commissioner of Lobbying of Canada. Canada does not require lobbyists to disclose what they spend, so there is no lobbying budget to report here — only the meetings they filed.